An interprofessional experience in diabetes management for pharmacy and medical students.

Background And Purpose: The 2016 Standards of the Accreditation Council for Pharmacy Education state that curricula must include opportunities for interprofessional education (IPE). This report describes a collaborative effort between a pharmacy program and a school of medicine to develop, implement, and evaluate an interprofessional workshop focused on collaborative disease management.

Educational Activity And Setting: A medical school course in diabetes management was identified as optimal for an IPE approach.

Treatment and managed care issues of atopic dermatitis.

The specific cause of atopic dermatitis (AD) is not known. It is a multifactorial disease involving environmental agents, immune dysregulation, genetic predisposition, and defects in skin barrier function. Patients are typically classified as having mild, moderate, or severe disease.

New therapeutic alternatives for the management of dyslipidemia.

Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of coronary heart disease (CHD). Conventional therapies, such as statins, have demonstrated their ability to improve clinical end points and decrease morbidity and mortality in patients with CHD. Lomitapide (Juxtapid(®)), mipomersen (Kynamro(®)), and icosapent (Vascepa(®)) are 3 novel agents approved by the US Food and Drug Administration in the past 2 years, which offer new lipid-lowering treatment options with unique pharmacology.

Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.

Purpose: The case of a patient who treated withdrawal symptoms from trans-dermal scopolamine with meclizine is reported.

Summary: A 30-year-old woman for whom transdermal scopolamine was prescribed to manage motion sickness during a vacation experienced severe withdrawal symptoms that began 24 hours after patch removal and lasted for several days. Other medications included an oral contraceptive and as-needed zolmitriptan for migraines.

Facial flushing associated with duloxetine use.

Purpose: A case of flushing associated with duloxetine use is presented.

Summary: A 43-year-old nonmenopausal woman was prescribed duloxetine 20 mg daily for migraine prophylaxis after the usual medications for treatment and prevention of migraines were used with little or no success. Magnetic resonance imaging and computed tomography ruled out structural causes of migraines.